Supplementary File
Laboratory Analyses:
NT-proBNP
NT-proBNP was measured on the Dimension Vista 500 Intelligent Laboratory System (Siemens
Healthcare Diagnostics, Deerfield, IL) using a one-step homogeneous, sandwich chemiluminescent
immunoassay based on LOCI® technology. The limit of detection of NT-proBNP assay is 0.8 pg/mL.
Typical within-lab imprecision for the assay is <3% CV at an NT-proBNP concentration from 120- 5000
pg/mL.
Troponin I
Precommercial ultrasensitive troponinI (TnI) was measured on the Dimension Vista 500 Intelligent
Laboratory System (Siemens Healthcare Diagnostics, Deerfield, IL) using a one-step homogeneous,
sandwich chemiluminescent immunoassay based on LOCI® technology. The lower limit of detection of
the troponin assay is 0.015 μg/L and the 10% CV is <0.04 μg/L.
sFlt-1
sFlt-1 was measured using a prototype ARCHITECT immunoassay (Abbott Laboratories, Abbott Park,
IL) utilizing the 2-step chemiluminescent microparticle immunoassay (CMIA) format. The sFlt-1
immunoassay measures both free and bound sFlt-1, with an measuring range of 15 to 50,000 pg/ml. The
intra- and interassay coefficients of variation (CV) ranged from 1.3% to 5.2% and 1.9% to 5.9%,
respectively.
PlGF
PlGF was measured using a prototype ARCHITECT immunoassay (Abbott Laboratories, Abbott Park,
IL) utilizing the 2-step chemiluminescent microparticle immunoassay (CMIA) format. The PlGF
immunoassay measures the free, not bound PlGF-1 with approximately 20% cross-reactivity with the
PlGF-2 isoform, with an measuring range from 1 to 1,500pg/ml. The intra- and interassay CV ranged
from 1.4% to 6.7% and 1.8% to 6.7%, respectively.
hsCRP
hsCRP was measured using the MULTIGENT Vario assay on the ARCHITECT ® system (Abbott
Laboratories, Abbott Park, IL), which is a latex immunoassay. The lower limit of detection if 0.01mg/dL.
The total CV was ≤ 6%.
MPO
MPO was measured using a prototype ARCHITECT immunoassay (Abbott Laboratories, Abbott Park,
IL) utilizing the 2-step chemiluminescent microparticle immunoassay (CMIA) format. The MPO
immunoassay has a measuring interval of 50 to 10,000 pmol/L. The intra- and interassay CV ranged from
1.8% to 7.6% and 3.2% to 9.8%, respectively.
Gal-3
Gal-3 was measured using a prototype ARCHITECT immunoassay (Abbott Laboratories, Abbott Park,
IL) utilizing the 2-step chemiluminescent microparticle immunoassay (CMIA) format. The gal-3
immunoassay has a measuring interval of 4.0 to 114.0 ng/mL. The intra- and interassay CV ranged from
0.9% to 6.7% and 1.4% to 8.6%, respectively.
GDF-15
GDF-15 was measured using a prototype ARCHITECT immunoassay (Abbott Laboratories, Abbott Park,
IL) utilizing the 2-step chemiluminescent microparticle immunoassay (CMIA) format. The GDF-15
immunoassay has a measuring interval of 10 to 25,000 pg/mL. The intra- and interassay CV ranged from
1.6% to 4.4% and 1.8% to 4.5%, respectively.
Supplementary Figure 1: Maximum Changes in LVEF According to Cardiotoxicity
Supplementary Figure 2: Distribution of changes in TnI and MPO (top row). Black lines in the
histograms indicate the values of the 10th and 90th percentiles for TnI and MPO.
Supplementary Figure 3: Kaplan-Meier plots for <10th (blue), 10th-90th (green) and >90th (red)
percentiles of change in TnI and MPO.